The risk of pneumonia-related hospitalization increased the most for patients using non-TNFi biologics, climbing by 257% compared with controls.
Individuals living with rheumatoid arthritis (RA) face significantly higher risks of developing pneumonia and being hospitalized due to the infection, according to a study published in BMJ Open Respiratory Research.1
The analysis further revealed that serologic status and the type of disease-modifying antirheumatic drugs (DMARDs) used can influence susceptibility, underscoring the importance of infection prevention strategies in this patient population.
“Pneumococcal vaccination, as well as other viral vaccinations including influenza vaccination, might be an appropriate preventive strategy,” researchers said.
The nationwide cohort study drew on Korea’s National Health Insurance Service database, enrolling 41,187 individuals with RA and 205,935 matched controls between 2010 and 2017. After excluding patients with prior pneumonia, participants were followed for a median of 4.2 years.
Serologic status and DMARD type may influence susceptibility to infection. | Image credit: agenturfotografin – stock.adobe.com
During this period, RA was associated with a 73% higher adjusted risk of pneumonia (95% CI, 1.69-1.78) and a 126% higher risk of pneumonia-related hospitalization (95% CI, 2.15-2.37) compared with controls. A prior study looking at the link between RA and pneumonia reported a 68% increased risk of pneumonia and an 84% increased risk of pneumonia-related hospitalization in patients with RA compared with those without.2
The study stratified RA cases into seropositive RA (SPRA, n = 28,516) and seronegative RA (SNRA, n = 12,671).1 Both subgroups demonstrated higher risk than controls, but outcomes were notably worse in seropositive disease.
Patients with SPRA had an 86% higher risk of pneumonia (95% CI, 1.80-1.92) and a 152% higher risk of pneumonia-related hospitalization (95% CI, 2.39-2.65) compared with controls. Patients with SNRA also showed elevated risk, but to a lesser degree, with a 43% higher risk for pneumonia and 60% for hospitalization.
Compared with SNRA, SPRA was linked to a 29% higher risk of pneumonia and a 58% higher risk of hospitalization. Researchers noted that seropositivity may reflect greater systemic inflammation and disease severity, contributing to increased infection vulnerability.
“The reasons for the increased risk of pneumonia and pneumonia-related hospitalisation in SPRA compared with SNRA cannot be explained fully by our results because our study is observational,” the authors noted. “However, for the underlying mechanism of this observation, we suggest that SPRA has a stronger systemic inflammatory response to the more aggressive immunosuppressive treatments compared with SNRA.”
Researchers also examined how different DMARD classes affected pneumonia outcomes. Conventional synthetic DMARDs were associated with a 74% higher risk of pneumonia and a 122% higher risk of hospitalization
This trend persisted with biologic DMARDs. Patients using tumor necrosis factor inhibitors (TNFi) had a 75% higher risk of pneumonia and a 189% increased risk of hospitalization. The risk of pneumonia was slightly lower for those using non-TNFi biologics, increasing by 56%, but the hospitalization risk was highest for this group, increasing by 257%. Targeted synthetic DMARDs such as tofacitinib did not show a significantly increased risk of pneumonia (aHR, 0.93) or hospitalization (aHR, 1.21).
According to the authors, further studies should examine how disease activity, glucocorticoid use, and vaccination status intersect with pneumonia risk.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen